Literature DB >> 15203934

Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system.

Gary Beale1, Andrew J Hollins, Mustapha Benboubetra, Muhammad Sohail, Stephen P Fox, Ibrahim Benter, Saghir Akhtar.   

Abstract

Gene silencing nucleic acids such as ribozymes, DNA enzymes (DNAzymes), antisense oligonucleotides (ODNs), and small interfering (si)RNA rely on hybridization to accessible sites within target mRNA for activity. However, the accurate prediction of hybridization accessible sites within mRNAs for design of effective gene silencing reagents has been problematic. Here we have evaluated the use of scanning arrays for the effective design of ribozymes, DNAzymes and siRNA sequences targeting the epidermal growth factor receptor (EGFR) mRNA. All three gene silencing nucleic acids designed to be complementary to the same array-defined hybridization accessible-site within EGFR mRNA were effective in inhibiting the growth of EGFR over-expressing A431 cancer cells in a dose dependent manner when delivered using the cationic lipid (Lipofectin) delivery system. Effects on cell growth were correlated in all cases with concomitant dose-dependent reduction in EGFR protein expression. The control sequences did not markedly alter cell growth or EGFR expression. The ribozyme and DNAzyme exhibited similar potency in inhibiting cell growth with IC50 values of around 750 nM. In contrast, siRNA was significantly more potent with an IC50 of about 100 nM when delivered with Lipofectin. The potency of siRNA was further enhanced when Oligofectamine was used to further improve both the cellular uptake and subcellular distribution of fluorescently labelled siRNA. Our studies show that active siRNAs can be designed using hybridization accessibility profiles on scanning arrays and that siRNAs targeting the same array-designed hybridization accessible site in EGFR mRNA and delivered using the same delivery system are more potent than ribozymes and DNAzymes in inhibiting EGFR expression in A431 cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15203934     DOI: 10.1080/1061186042000207039

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  8 in total

1.  siRNAs target sites selection of ezrin and the influence of RNA interference on ezrin expression and biological characters of osteosarcoma cells.

Authors:  XiFu Shang; YaoFei Wang; QiChun Zhao; KeRong Wu; Xu Li; XiaoFeng Ji; Rui He; WenZhi Zhang
Journal:  Mol Cell Biochem       Date:  2012-05       Impact factor: 3.396

Review 2.  Nonviral delivery of synthetic siRNAs in vivo.

Authors:  Saghir Akhtar; Ibrahim F Benter
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 3.  Lipid-based vectors for siRNA delivery.

Authors:  Shubiao Zhang; Defu Zhi; Leaf Huang
Journal:  J Drug Target       Date:  2012-09-20       Impact factor: 5.121

Review 4.  Therapeutic potential of siRNA and DNAzymes in cancer.

Authors:  Hanuma Kumar Karnati; Ravi Shekar Yalagala; Rambabu Undi; Satya Ratan Pasupuleti; Ravi Kumar Gutti
Journal:  Tumour Biol       Date:  2014-08-23

5.  Ezrin mRNA target site selection for DNAzymes using secondary structure and hybridization thermodynamics.

Authors:  YaoFei Wang; JingNan Shen; XiFu Shang; Jin Wang; JingChun Li; JunQiang Yin; ChangYe Zou
Journal:  Tumour Biol       Date:  2011-05-11

Review 6.  Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA.

Authors:  Maria Abdul Ghafoor Raja; Haliza Katas; Muhammad Wahab Amjad
Journal:  Asian J Pharm Sci       Date:  2019-02-13       Impact factor: 6.598

Review 7.  Modulation of angiogenesis with siRNA inhibitors for novel therapeutics.

Authors:  Patrick Y Lu; Frank Y Xie; Martin C Woodle
Journal:  Trends Mol Med       Date:  2005-03       Impact factor: 11.951

8.  Systematic analysis of the role of target site accessibility in the activity of DNA enzymes.

Authors:  Graeme Doran; Muhammad Sohail
Journal:  J RNAi Gene Silencing       Date:  2006-07-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.